ABOUT US

A global leader in innovative genomic
technology and diagnostic tests.


What’s new at Agendia?

Get the latest updates on our company and products, as well as new developments in genomic science.

News

In the News

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

Two women reading about genomic breast cancer results

Latest Data

Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […]

I Am Here breast cancer illustration

Patient News

Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series illustrating people touched by breast cancer.

News

Media Releases

Agendia’s MammaPrint First and Only Genomic Assay to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients

April 18th, 2016|

Clinical high-risk patients with a low-risk MammaPrint® result, including 48 percent node-positive, had five-year distant metastasis-free survival rate in excess of 94 percent, whether randomized to receive adjuvant chemotherapy or not MammaPrint could change clinical Read More